Ampio Pharmaceuticals Inc was formerly known as Chay Enterprises, Inc. On March 2, 2010, the Company entered into an Agreement and Plan of Merger, with DMI Life Sciences, Inc., a Delaware corporation, or DMI and Chay Acquisitions, Inc., a Delaware corporation and its wholly-owned subsidiary which was incorporated in February 2010. At the closing of the transaction, Chay Acquisitions was merged into DMI and DMI, as the Surviving Corporation, became its wholly-owned subsidiary. As a result, the Company is no longer engaged in the real estate business and its business is now that of DMI. The Company is a development stage biopharmaceutical company which is engaged in developing innovative, proprietary pharmaceutical drugs and diagnostic products to identify, treat and prevent a range of human diseases including metabolic disorders, cancer and acute and chronic inflammation diseases. On 1 March 2010 the Company changed its name to Ampio Pharmaceuticals, Inc. The Company develops drugs to treat metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The Company's product pipeline includes certain FDA approved drugs, now targeted at new clinical indications protected by its intellectual property and new molecular entities (NMEs). It is actively exploring partnership, licensing and other collaboration opportunities to maximize its near term and long term product development programs. The Company is also developing a handheld oxidation-reduction potential diagnostic device for use at home or in healthcare facilities that will measure the oxidants/antioxidant balances in human blood and plasma; and methylphenidate derivatives for cancer, which are in pre-clinical development.